Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point of care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: 5,100 physician authors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

For more information, click below.


Subscribers log in here


Clinical manifestations and diagnosis of acute intermittent porphyria

INTRODUCTION

Acute intermittent porphyria (AIP, Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is an autosomal dominant disorder resulting from a partial deficiency of porphobilinogen deaminase (PBGD, hydroxymethylbilane synthase, previously called uroporphyrinogen I synthase), the third enzyme in the heme biosynthetic pathway (figure 1 and figure 2). Symptoms in AIP are due to effects on the visceral, peripheral, autonomic, and central nervous systems. They usually occur as intermittent attacks that are sometimes life-threatening [1,2].

The clinical manifestations and diagnosis of AIP will be reviewed here. The etiology, pathogenesis, and management of AIP and an overview of the porphyrias are discussed separately. (See "Etiology and pathogenesis of acute intermittent porphyria" and "Management of acute intermittent porphyria" and "Porphyrias: An overview".)

CLINICAL MANIFESTATIONS

Most individuals with acute intermittent porphyria (AIP, ie, those who inherit a porphobilinogen deaminase mutation) never develop symptoms. Accordingly, symptomatic disease may skip generations or be recognized in only one individual within a family. The presentation is highly variable and the symptoms are nonspecific, which accounts in part for delays in diagnosis. Symptoms usually occur as acute attacks, most often in the third or fourth decades of life, and are more common in women than in men. The most common manifestations of AIP are listed in the table (table 1).

Attacks in AIP develop over hours or days and persist for days or weeks, depending upon precipitating factors and treatment. There are no cutaneous manifestations. Rare exceptions are patients with AIP and advanced renal failure, who may develop elevations in plasma porphyrins and blistering skin lesions [2,3].

Abdominal and urinary symptoms — Abdominal pain is the most common symptom in AIP, occurring in 85 to 95 percent of patients with acute attacks (table 1). It is usually severe, steady, and poorly localized but is sometimes cramping, and is often accompanied by constipation and signs of ileus such as nausea, vomiting, abdominal distension, and decreased bowel sounds. However, diarrhea and increased bowel sounds are sometimes seen.

             

Subscribers log in here

To continue reading this article you must have access through your hospital or your group practice, log in to your personal subscription, or purchase a personal subscription. For more information, click below.
Literature review current through: 20.6: May 2012
This topic last updated: Apr 10, 2012
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2012 UpToDate, Inc.
References
Top
  1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: The Metabolic and Molecular Basis of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et al. (Eds), McGraw-Hill, New York 2001. p.2991.
  2. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439.
  3. Sardh E, Andersson DE, Henrichson A, Harper P. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand) 2009; 55:66.
  4. Waldenstrom J. The porphyrias as inborn errors of metabolism. Am J Med 1957; 22:758.
  5. Tschudy DP, Valsamis M, Magnussen CR. Acute intermittent porphyria: clinical and selected research aspects. Ann Intern Med 1975; 83:851.
  6. Stein JA, Tschudy DP. Acute intermittent porphyria. A clinical and biochemical study of 46 patients. Medicine (Baltimore) 1970; 49:1.
  7. Ridley A. Porphyric neuropathy. In: Peripheral neuropathy, Dyck PJ, Thomas PK, Lambert EH, Bunge R (Eds), WB Saunders Co, Philadelphia 1984. p.1704.
  8. Wikberg A, Andersson C, Lithner F. Signs of neuropathy in the lower legs and feet of patients with acute intermittent porphyria. J Intern Med 2000; 248:27.
  9. Beal MF, Atuk NO, Westfall TC, Turner SM. Catecholamine uptake, accumulation, and release in acute porphyria. J Clin Invest 1977; 60:1141.
  10. Sze G. Cortical brain lesions in acute intermittent porphyria. Ann Intern Med 1996; 125:422.
  11. Jeans JB, Savik K, Gross CR, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet 1996; 65:269.
  12. Ostrowski J, Kostrzewska E, Michalak T, et al. Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology 1983; 85:1131.
  13. Bylesjö I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest 2009; 69:612.
  14. Andant C, Puy H, Bogard C, et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 2000; 32:933.
  15. Andant C, Puy H, Faivre J, Deybach JC. Acute hepatic porphyrias and primary liver cancer. N Engl J Med 1998; 338:1853.
  16. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 1996; 240:195.
  17. Bengtsson NO, Hardell L. Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer 1986; 54:115.
  18. Gubler JG, Bargetzi MJ, Meyer UA. Primary liver carcinoma in two sisters with acute intermittent porphyria. Am J Med 1990; 89:540.
  19. Hardell L, Bengtsson NO, Jonsson U, et al. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria--an epidemiological investigation. Br J Cancer 1984; 50:389.
  20. Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 1988; 57:117.
  21. Linet MS, Gridley G, Nyrén O, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999; 149:1010.
  22. Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand 1984; 215:271.
  23. Church SE, McColl KE, Moore MR, Youngs GR. Hypertension and renal impairment as complications of acute porphyria. Nephrol Dial Transplant 1992; 7:986.
  24. Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med 2000; 248:319.
  25. Marsden JT, Chowdhury P, Wang J, et al. Acute intermittent porphyria and chronic renal failure. Clin Nephrol 2008; 69:339.
  26. Barone GW, Gurley BJ, Anderson KE, et al. The tolerability of newer immunosuppressive medications in a patient with acute intermittent porphyria. J Clin Pharmacol 2001; 41:113.
  27. Hultdin J, Schmauch A, Wikberg A, et al. Acute intermittent porphyria in childhood: a population-based study. Acta Paediatr 2003; 92:562.
  28. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 2002; 48:1891.
  29. Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem 1998; 35 ( Pt 6):726.
  30. Floderus Y, Sardh E, Möller C, et al. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Clin Chem 2006; 52:701.
  31. Anderson KE, Sassa S, Peterson CM, Kappas A. Increased erythrocyte uroporphyrinogen-l-synthetase, delta-aminolevulinic acid dehydratase and protoporphyrin in hemolytic anemias. Am J Med 1977; 63:359.
  32. Blum M, Koehl C, Abecassis J. Variations in erythrocyte uroporphyrinogen I synthetase activity in non porphyrias. Clin Chim Acta 1978; 87:119.
  33. Kostrzewska E, Gregor A. Increased activity of porphobilinogen deaminase in erythrocytes during attacks of acute intermittent porphyria. Ann Clin Res 1986; 18:195.
  34. Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 1980; 116:543.
  35. Blake D, McManus J, Cronin V, Ratnaike S. Fecal coproporphyrin isomers in hereditary coproporphyria. Clin Chem 1992; 38:96.
  36. Gibson PR, Grant J, Cronin V, et al. Effect of hepatobiliary disease, chronic hepatitis C and hepatitis B virus infections and interferon-alpha on porphyrin profiles in plasma, urine and faeces. J Gastroenterol Hepatol 2000; 15:192.
  37. Akagi R, Kato N, Inoue R, et al. delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations. Mol Genet Metab 2006; 87:329.